原发性局限性肾细胞癌消融治疗的疗效与安全性比较:系统综述与Meta分析
该系统综述与Meta分析检索2000年1月1日至2024年3月1日文献,纳入133项观察性研究和随机对照试验、8910例原发性局限性肾细胞癌患者,比较立体定向体部放疗、射频消融、微波消融和冷冻消融的局部控制率与不良事件。立体定向体部放疗5年局部控制率为95%,射频消融为92%,微波消融为86%,冷冻消融为90%;3-4级不良事件比例分别为2%、2%、1%和3%。
要点
- 立体定向体部放疗5年局部控制率95%(95%CI 89-98),射频消融92%(88-96),微波消融86%(75-94),冷冻消融90%(87-93)。
- 3-4级不良事件比例:冷冻消融3%(121/3726),射频消融2%(39/2503),微波消融1%(22/2069),立体定向体部放疗2%(11/612)。
- 多数研究偏倚风险为中等(70/133,53%),未观察到发表偏倚。
核心结论
- 所有研究的消融方法仍是肾细胞癌的有效治疗选择,这些发现支持多学科讨论消融治疗与手术及监测,以个体化治疗决策。
- 未来研究应开展更大患者人群的随机对照试验,以进一步阐明这些治疗的长期肿瘤学和生存结局。
研究设计与样本
- 系统综述与Meta分析,检索PubMed(MEDLINE)、Embase和Cochrane Library 2000年1月1日至2024年3月1日的文献。
- 纳入观察性研究和随机对照试验,要求至少5例年龄≥18岁的原发性局限性肾细胞癌成人患者接受立体定向体部放疗、射频消融、微波消融或冷冻消融并报告局部控制结局。
- 共识别6668条记录,330篇全文评估,最终纳入133项研究,包含8910例患者(平均年龄67.9岁[SD 7.3],有数据可用的8018例中女性2518例[31.4%]、男性5500例[68.6%])。
- 主要终点为治疗开始后1年、2年和5年的局部控制率,采用DerSimonian and Laird模型汇总,漏斗图和Egger检验评估发表偏倚。
- 研究方案前瞻性注册于PROSPERO,CRD42024511840。
主要发现
- 立体定向体部放疗局部控制率:1年99%(95%CI 97-100;I²=6%),2年97%(95-99;I²=0%),5年95%(89-98;I²=42%)。
- 射频消融局部控制率:1年96%(94-98;I²=73%),2年95%(92-98;I²=77%),5年92%(88-96;I²=78%)。
- 微波消融局部控制率:1年97%(95-99;I²=74%),2年95%(92-98;I²=77%),5年86%(75-94;I²=66%)。
- 冷冻消融局部控制率:1年95%(93-96;I²=61%),2年94%(91-96;I²=69%),5年90%(87-93;I²=74%)。
- 3-4级不良事件比例:冷冻消融3%(121/3726),射频消融2%(39/2503),微波消融1%(22/2069),立体定向体部放疗2%(11/612);多数研究偏倚风险为中等(70/133,53%),未观察到发表偏倚。
关键数值与推荐
- 立体定向体部放疗5年局部控制率95%(95%CI 89-98;I²=42%)。
- 射频消融5年局部控制率92%(95%CI 88-96;I²=78%)。
- 微波消融5年局部控制率86%(95%CI 75-94;I²=66%)。
- 冷冻消融5年局部控制率90%(95%CI 87-93;I²=74%)。
- 3-4级不良事件:冷冻消融3%(121/3726),射频消融2%(39/2503),微波消融1%(22/2069),立体定向体部放疗2%(11/612)。
临床怎么用
- 作者认为所有研究的消融方法仍是肾细胞癌的有效治疗选择。
- 作者认为这些发现支持多学科讨论消融治疗与手术及监测,以个体化治疗决策。
- 作者建议未来研究应开展更大患者人群的随机对照试验,以进一步阐明长期肿瘤学和生存结局。
局限性
- 多数研究偏倚风险为中等(70/133,53%)。
- 未来研究应开展更大患者人群的随机对照试验,以进一步阐明这些治疗的长期肿瘤学和生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-invasive and minimally invasive ablative treatments, including stereotactic body radiotherapy (SBRT), radiofrequency ablation, microwave ablation, and cryoablation, have emerged as key treatment options for managing renal cell carcinoma, especially for patients who are unsuitable for surgery. We aimed to compare the clinical efficacy and safety of these emerging treatment methods in patients with localised renal cell carcinoma. METHODS: In this systematic review and meta-analysis, we searched PubMed (MEDLINE), Embase, and the Cochrane Library for publications between Jan 1, 2000, and March 1, 2024. Eligible articles were observational studies and randomised controlled trials including at least five adult patients (age ≥18 years) with primary and localised renal cell carcinoma treated with SBRT, radiofrequency ablation, microwave ablation, or cryoablation and that reported on local control outcomes. Two reviewers independently screened titles and abstracts and then full texts of eligible studies were independently evaluated by the same reviewers, with disagreements resolved via discussion or consultation with a third reviewer. Summary estimates were extracted from published reports manually using a standardised data extraction form. The primary endpoint was local control rate at 1 year, 2 years, and 5 years after start of treatment. A meta-analysis was conducted using a DerSimonian and Laird model to summarise local control rates. Publication bias was evaluated using funnel plots and Egger's test. We also recorded the frequency and severity of adverse events after treatment on the basis of the Common Terminology Criteria for Adverse Events (version 5.0) and Clavien-Dindo complication index. The study protocol was prospectively registered with PROSPERO, CRD42024511840. FINDINGS: We identified 6668 records, of which 330 were assessed via full-text review, and 133 were included in our systematic review and meta-analysis. The eligible studies included data for 8910 patients (mean age 67·9 years [SD 7·3], 2518 [31·4%] of 8018 patients with available data were female and 5500 [68·6%] were male). Local control rates for SBRT were 99% (95% CI 97-100; I2=6%) at 1 year, 97% (95-99; I2=0%) at 2 years, and 95% (89-98; I2=42%) at 5 years; for radiofrequency ablation were 96% (94-98; I2=73%) at 1 year, 95% (92-98; I2=77%) at 2 years, and 92% (88-96; I2=78%) at 5 years; for microwave ablation were 97% (95-99; I2=74%) at 1 year, 95% (92-98; I2=77%) at 2 years, and 86% (75-94; I2=66%) at 5 years; and for cryoablation were 95% (93-96; I2=61%) at 1 year, 94% (91-96; I2=69%) at 2 years, and 90% (87-93; I2=74%) at 5 years. The proportion of patients who reported grade 3-4 adverse events was 3% (121 of 3726) after cryoablation, 2% (39 of 2503) after radiofrequency ablation, 1% (22 of 2069) after microwave ablation, and 2% (11 of 612) after SBRT. Risk of bias was moderate in most studies (70 [53%] of 133) and no publication bias was observed. INTERPRETATION: All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along with surgery and surveillance, to individualise treatment decisions in these patients. Future research should aim to conduct randomised controlled trials across larger patient populations to further elucidate the long-term oncological and survival outcomes associated with these treatments. FUNDING: None.
引用
- Huang RS, Chow R, Benour A, et al. Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2025. PMID: 39922208. doi:10.1016/S1470-2045(24)00731-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。